EAN 2023 | Latest regarding SMA biomarkers for disease monitoring and treatment response

Robert Muní-Lofra, PhD, University of Newcastle, Newcastle, UK, goes into detail on the latest advancements in disease monitoring and treatment response utilizing spinal muscular atrophy (SMA) biomarkers. From a neurological standpoint, biomarkers remain a valuable tool to measure disease progression. However, current measures may not capture certain aspects of the disease, such as fatigue and respiratory changes. Dr Muní-Lofra elaborates on how the medical community is evolving its approach to disease assessment and intervention. This interview took place at the European Academy of Neurology (EAN) 2023 Congress in Budapest, Hungary.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.